Gynecologic Cancer News

An electronic, odor-based tool accurately distinguished pancreatic and ovarian cancer specimens from benign disease and control specimens by analyzing vapors emanating from blood samples, according to results of a small, preliminary study.

In this video, Stephen C. Rubin, MD, professor and chief of the division of gynecologic oncology and Grotzinger-Raab Chair in Surgical Oncology at Fox Chase Cancer Center in Philadelphia, discussed the OUTBACK trial presented at the ASCO Annual Meeting.

In this video, Stephen C. Rubin, MD, professor and chief of the division of gynecologic oncology and Grotzinger-Raab Chair in Surgical Oncology at Fox Chase Cancer Center in Philadelphia, spoke with Healio about mirvetuximab, which “has generated considerable excitement and interest as an anti-ovarian cancer agent.”

In this video, Stephen C. Rubin, MD, professor and chief of the division of gynecologic oncology and Grotzinger-Raab Chair in Surgical Oncology at Fox Chase Cancer Center in Philadelphia, spoke with Healio about a study evaluating the optimal treatment duration of bevacizumab combined with carboplatin and paclitaxel in patients with primary epithelial ovarian cancer, fallopian tube cancer or peritoneal cancer.

Mirvetuximab soravtansine in combination with bevacizumab demonstrated antitumor activity with durable responses and favorable tolerability among women with high folate receptor-alpha recurrent ovarian cancer, according to study results.

A novel vaccine appeared safe and demonstrated clinical benefit as front-line maintenance therapy for women with advanced-stage ovarian cancer, according to results of a phase 2b trial presented during the virtual ASCO Annual Meeting.

Use of alrizomadlin with pembrolizumab appeared to restore the antitumor effects of the anti-PD-1 antibody among patients with melanoma resistant to or intolerant of immunotherapy, according to phase 2 study results.

Adavosertib alone and in combination with olaparib demonstrated efficacy among women with poly(ADP-ribose) polymerase (PARP) inhibitor-resistant ovarian cancer, according to study results presented during the virtual ASCO Annual Meeting.

IACS-6274, a selective glutaminase-1 inhibitor, appeared safe and demonstrated antitumor activity among patients with biomarker-selected advanced solid tumors, according to phase 1 study results presented at the virtual ASCO Annual Meeting.

Adjuvant chemotherapy following chemoradiation did not prolong OS or PFS compared with chemoradiation alone among women with locally advanced cervical cancer, according to results of the randomized phase 3 OUTBACK study.